Open an account

Galmed Pharmaceuticals

EOCN · NASDAQ

$3.07+$0.22 (+7.72%)TodayMarket closed ·
Prev close $2.85

About EOCN

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

Employees
3
Headquarters
Ramat Gan
Listed
Mar 13, 2014
Sector
Health Care
Industry
Biotechnology
Website
galmedpharma.com

EOCN key statistics

Market cap
3.20M
Price-earnings ratio
—
Dividend yield
—
Average volume
7.90K
Volume
6.62K
Open price
$2.87
High today
$3.07
Low today
$2.82
52 Week high
$12.32
52 Week low
$2.33

Galmed Pharmaceuticals (EOCN) at a glance

Galmed Pharmaceuticals (EOCN) last traded at $3.07, with a market cap of 3.20M.

Today the stock has traded between $2.82 and $3.07. The current price is 8.9% above the day's low and 0.0% below its high.

Volume so far is 6.62K shares, in line with the average of 7.90K shares a day.

Over the past year Galmed Pharmaceuticals has ranged from $2.33 to $12.32, and now sits 7% of the way up that range.

Galmed Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$2.86 per share against an estimate of -$3.18.

EOCN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 24.3% on average.

  1. Q3 FY23: reported -$23.04 per share against an estimate of -$26.44
  2. Q4 FY23: reported -$94.08 per share against an estimate of -$31.33
  3. Q1 FY25: reported -$4.96 per share against an estimate of -$7.26
  4. Q2 FY25: reported -$5.04 per share against an estimate of -$6.77
  5. Q3 FY25: reported -$2.64 per share against an estimate of -$4.41
  6. Q4 FY25: reported -$6.40 per share against an estimate of -$4.16
  7. Q1 FY26: reported -$2.32 per share against an estimate of -$3.10
  8. Q2 FY26: reported -$2.86 per share against an estimate of -$3.18

EOCN news

  • Press releasePRNewswire

    Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

Similar companies

Companies in the same industry as Galmed Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.